IN2015DN02667A - - Google Patents
Info
- Publication number
- IN2015DN02667A IN2015DN02667A IN2667DEN2015A IN2015DN02667A IN 2015DN02667 A IN2015DN02667 A IN 2015DN02667A IN 2667DEN2015 A IN2667DEN2015 A IN 2667DEN2015A IN 2015DN02667 A IN2015DN02667 A IN 2015DN02667A
- Authority
- IN
- India
- Prior art keywords
- amino
- human
- pharmaceutically acceptable
- acceptable salt
- relates
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712869P | 2012-10-12 | 2012-10-12 | |
| US201361833561P | 2013-06-11 | 2013-06-11 | |
| PCT/US2013/064260 WO2014059095A1 (en) | 2012-10-12 | 2013-10-10 | Combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN02667A true IN2015DN02667A (enExample) | 2015-09-04 |
Family
ID=50477878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2667DEN2015 IN2015DN02667A (enExample) | 2012-10-12 | 2013-10-10 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160263116A1 (enExample) |
| EP (1) | EP2906215A4 (enExample) |
| JP (1) | JP2015533165A (enExample) |
| KR (1) | KR20150067323A (enExample) |
| CN (1) | CN104755079A (enExample) |
| AU (1) | AU2013329199A1 (enExample) |
| BR (1) | BR112015008155A2 (enExample) |
| CA (1) | CA2888094A1 (enExample) |
| IN (1) | IN2015DN02667A (enExample) |
| RU (1) | RU2015117483A (enExample) |
| WO (1) | WO2014059095A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2779975T3 (es) | 2014-02-07 | 2020-08-21 | Verastem Inc | Métodos y composiciones para tratar el crecimiento celular anormal |
| GB201510628D0 (en) * | 2015-06-17 | 2015-07-29 | Glaxosmithkline Ip No 2 Ltd | Novel use |
| JP2022547358A (ja) | 2019-09-13 | 2022-11-14 | ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル | 治療組成物、組み合わせ、及び使用方法 |
| US20230201179A1 (en) * | 2020-04-08 | 2023-06-29 | Aptabio Therapeutics Inc. | Agent for treating contrast-induced acute kidney injury |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA022637B1 (ru) * | 2009-11-17 | 2016-02-29 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Комбинация |
| WO2012045194A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| CN103476413B (zh) * | 2011-01-26 | 2016-03-16 | 葛兰素史密斯克莱知识产权有限公司 | 组合 |
-
2013
- 2013-10-10 IN IN2667DEN2015 patent/IN2015DN02667A/en unknown
- 2013-10-10 KR KR1020157011950A patent/KR20150067323A/ko not_active Withdrawn
- 2013-10-10 US US14/680,416 patent/US20160263116A1/en not_active Abandoned
- 2013-10-10 CA CA2888094A patent/CA2888094A1/en not_active Abandoned
- 2013-10-10 JP JP2015536880A patent/JP2015533165A/ja active Pending
- 2013-10-10 WO PCT/US2013/064260 patent/WO2014059095A1/en not_active Ceased
- 2013-10-10 EP EP13845429.3A patent/EP2906215A4/en not_active Withdrawn
- 2013-10-10 CN CN201380055435.XA patent/CN104755079A/zh active Pending
- 2013-10-10 RU RU2015117483A patent/RU2015117483A/ru not_active Application Discontinuation
- 2013-10-10 BR BR112015008155A patent/BR112015008155A2/pt not_active IP Right Cessation
- 2013-10-10 AU AU2013329199A patent/AU2013329199A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013329199A1 (en) | 2015-04-16 |
| BR112015008155A2 (pt) | 2017-07-04 |
| CN104755079A (zh) | 2015-07-01 |
| RU2015117483A (ru) | 2016-12-10 |
| EP2906215A1 (en) | 2015-08-19 |
| WO2014059095A1 (en) | 2014-04-17 |
| CA2888094A1 (en) | 2014-04-17 |
| EP2906215A4 (en) | 2016-05-18 |
| JP2015533165A (ja) | 2015-11-19 |
| US20160263116A1 (en) | 2016-09-15 |
| KR20150067323A (ko) | 2015-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002321A (es) | Nuevos metodos. | |
| EA201590870A1 (ru) | АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| PH12012501740A1 (en) | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate | |
| MY191357A (en) | Sustained-release dosage forms of ruxolitinib | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| HK1205941A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
| WO2015021358A3 (en) | Compounds and methods for inhibiting phosphate transport | |
| WO2013169704A3 (en) | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | |
| GEP201706786B (en) | Methods and drug products for treating alzheimer's disease | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| IN2015DN00450A (enExample) | ||
| EA201691695A1 (ru) | Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат | |
| ZA201806684B (en) | Methods of treating pediatric cancers | |
| HK1206726A1 (en) | Imidazotriazinone compounds | |
| IL262177B (en) | Pyrimidinyl Carboxamide, 5-a] compounds and their use for the treatment of medical disorders | |
| MX383665B (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| IL233557A0 (en) | Use of lequinimod for the treatment of Crohn's disease in which the anti-TN-AP alpha treatment has failed | |
| IN2015DN02667A (enExample) | ||
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| HK1218251A1 (zh) | 用拉喹莫德治疗多发性硬化症 | |
| MX356704B (es) | Combinación. | |
| MX2015000485A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. | |
| EA201270445A1 (ru) | Комбинация | |
| EA201500882A1 (ru) | Комбинация |